Pfizer Vows Appeal After India Revokes Sutent Patent

Law360, New York (October 5, 2012, 4:56 PM EDT) -- Pfizer Inc. said Friday that it would fight a ruling by the Indian Patent Office revoking a local patent for its cancer treatment drug Sutent, the latest in a string of setbacks for branded-drug companies involved in patent disputes in the country.

Pfizer said it plans to appeal the IPO's ruling before the Intellectual Property Appellate Board. The drugmaker also joined other pharmaceutical company's who have questioned whether India's patent system does enough to protect intellectual property rights.

“We believe the decision undermines intellectual property rights...
To view the full article, register now.